Cases & Deals

  • Home
  • Practices
  • Abogen Biosciences develops global patent portfolios related to RNA-based therapeutics

Share

Abogen Biosciences develops global patent portfolios related to RNA-based therapeutics

December 2023

Client(s) Suzhou Abogen Biosciences Co., Ltd.

Jones Day is representing Suzhou Abogen Biosciences Co., Ltd. in developing global patent portfolios related to innovative xRNA-based therapeutic platforms for oncology and autoimmune diseases, including a wide variety of drug modalities and delivery systems, including RNA-encoded antibodies, immune cell engagers, vaccines for infectious diseases or cancer, and targeted lipid nanoparticle (tLNP) technologies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.